Covered recipient · General Payments record
CASEY NICHOLE GREEN
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2022–2024
$674.46
- Reported across 35 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $311.67 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $60.31 | 3 |
| Mylan Specialty L.P. | $51.48 | 2 |
| Exact Sciences Corporation | $41.85 | 2 |
| Novo Nordisk AS | $36.86 | 2 |
| GlaxoSmithKline, LLC. | $33.52 | 2 |
| Lilly USA, LLC | $32.53 | 2 |
| Abbott Laboratories | $26.44 | 1 |
| PFIZER INC. | $14.79 | 1 |
| Phathom Pharmaceuticals, Inc. | $13.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $26.44 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125076388 | CMS |
| ABBVIE INC. | $18.92 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107248503 | CMS |
| ABBVIE INC. | $17.73 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107248505 | CMS |
| ABBVIE INC. | $23.66 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107248507 | CMS |
| Exact Sciences Corporation | $22.49 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114537401 | CMS |
| Exact Sciences Corporation | $19.36 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114537405 | CMS |
| GlaxoSmithKline, LLC. | $14.74 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116659823 | CMS |
| GlaxoSmithKline, LLC. | $18.78 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116229499 | CMS |
| Lilly USA, LLC | $15.40 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135618799 | CMS |
| Lilly USA, LLC | $17.13 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135602155 | CMS |
| Mylan Specialty L.P. | $26.56 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147349721 | CMS |
| Mylan Specialty L.P. | $24.92 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147373156 | CMS |
| Novo Nordisk Inc | $16.52 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100484965 | CMS |
| Novo Nordisk Inc | $20.34 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100600095 | CMS |
| PFIZER INC. | $14.79 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130972139 | CMS |
| Phathom Pharmaceuticals, Inc. | $13.89 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151169692 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.